Secondary analysis of an RCT in 54 adults with treatment-resistant depression: six weeks of daily low-dose oral esketamine did not change serum BDNF relative to placebo; BDNF rose in both groups and did not correlate with change in depression severity.
Secondary analysisn = 54
Massetti et al. Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial